Semaglutide Plus⁺
$99.97/month — All Dosages Same Price
Personalized GLP-1 Medication with B12 or Glycine
- ✓Same Price for All Dosages. No Membership Fees.
- ✓Premium personalized blend with B12 for Energy
- ✓Free overnight cold shipping. Ships in 72 hours.
- ✓Each batch undergoes extensive quality checks
What Is NewSelf Semaglutide Plus⁺?
NewSelf Semaglutide Plus⁺ is a compounded GLP-1 receptor agonist medication featuring a full dose of semaglutide, enhanced with either Cyanocobalamin (Vitamin B12) or Glycine to support weight loss and boost energy levels. It contains the same active ingredient as the brand-name medications Ozempic® (FDA-approved for type 2 diabetes) and Wegovy® (FDA-approved for chronic weight management) — but produced by NewSelf's partner 503A licensed compounding pharmacies at a substantially lower price point.
Semaglutide works as a GLP-1 receptor agonist: it mimics the gut hormone glucagon-like peptide-1, binding to GLP-1 receptors in the brain and gastrointestinal tract. This binding significantly suppresses appetite, slows gastric emptying (so food stays in the stomach longer), and reduces the mental "food noise" — the constant preoccupation with eating — that many overweight patients experience. The result is a physiological reduction in caloric intake rather than a willpower-dependent one.
The B12 enhancement in Semaglutide Plus⁺ addresses a practical concern: GLP-1-driven caloric restriction can reduce absorption of Vitamin B12 over time, and B12 deficiency affects energy metabolism and neurological function. By including Cyanocobalamin in the formulation, NewSelf aims to support energy levels and metabolic health alongside the weight-loss mechanism. Read our detailed guide: why the B12 + Glycine blend matters.
Clinical Evidence: How Much Weight Can Semaglutide Produce?
Semaglutide's weight-loss efficacy is among the most extensively documented of any pharmacological agent. The landmark STEP program — four phase-3 clinical trials conducted by Novo Nordisk and published in peer-reviewed journals — provides the most authoritative data:
- STEP-1 (NEJM, 2021): Adults with obesity, no diabetes. Semaglutide 2.4mg weekly: average 14.9% body weight loss over 68 weeks. 86.4% achieved ≥5% weight loss; 69.1% achieved ≥10% weight loss.
- STEP-2 (Lancet, 2021): Adults with type 2 diabetes. Average 9.6% body weight loss over 68 weeks.
- STEP-3 (JAMA, 2021): Semaglutide plus intensive behavioral therapy: 16% average weight loss.
NewSelf cites approximately 16% average body weight reduction in its semaglutide marketing materials, consistent with STEP-3 outcomes. It is important to note these are population-level trial averages — individual results depend on adherence, diet, activity level, starting weight, and metabolic factors. See our clinical sources page for full citation details.
Dosing and Administration
Compounded semaglutide from NewSelf is administered as a subcutaneous (under-the-skin) injection once weekly. Available dosage tiers range from 0.25mg to 2.5mg — and critically, all dosage tiers are priced the same at $99.97/month, unlike competitors who charge more for higher doses.
Your NewSelf provider determines your starting dose based on your health intake. GLP-1 medications are titrated upward gradually — typically starting at 0.25mg and increasing every 4 weeks as tolerated — to minimize gastrointestinal side effects. Each 3-month supply includes 20 syringes, cold packs, a dosage bag with storage info, and 10 swabs.
Injection sites: Abdomen, upper thigh, or outer upper arm. Rotate sites between injections. Confirm exact dose, concentration, and units with your provider before first injection — dosing errors are the most commonly reported adverse event with compounded injectable semaglutide.
Side Effects of Compounded Semaglutide
- Nausea (most common, weeks 1–8; typically diminishes as body adjusts)
- Constipation (manage with 64+ oz water daily and dietary fiber)
- Fatigue (often related to reduced caloric intake, not medication directly)
- Vomiting or diarrhea (less common; more likely with rapid dose escalation)
- Injection site reactions (mild redness, bruising — typically transient)
- Serious but rare: Pancreatitis, gallbladder disease, acute kidney injury
Contraindications: Not appropriate for individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Disclose full medical history at intake. See our safety guide for full context.
Compounded vs. Brand-Name Semaglutide
NewSelf's compounded semaglutide contains the same active ingredient — semaglutide — as Ozempic and Wegovy, but is produced by a 503A compounding pharmacy rather than Novo Nordisk. This is legally authorized during active FDA drug shortage periods. The FDA does not independently review compounded products for safety or efficacy the way it reviews brand-name drugs — quality assurance relies on the compounding pharmacy's own practices and third-party testing.
NewSelf's partner pharmacies use independent third-party lab testing (potency, sterility, endotoxicity) for each batch. The February 2026 FDA warning letter targeted NewSelf's marketing claims specifically — not the compounding pharmacies themselves. Read our FDA warning letter explainer for full context.
Pricing: How Much Does Semaglutide Plus⁺ Cost?
The promotional product page for Semaglutide Plus⁺ shows $99.97/month for all dosages — with no dose upcharges and no separate membership fee. This is one of the most competitive prices available for compounded semaglutide in the US telehealth market.
However, NewSelf's main homepage has at various times shown $134.99/month, and some older pages show higher figures. Always confirm the exact recurring charge at checkout before completing payment. The 3-month commitment means you are billed for at least 3 months. See our complete NewSelf cost guide for the full pricing analysis, commitment terms, and cancellation fee breakdown.